Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia.

A treatment strategy that combines arsenic trioxide (ATO) with the tyrosine kinase inhibitor imatinib mesylate (STI571, Gleevec) appears to induce markedly more cell apoptosis than imatinib mesylate alone in chronic myeloid leukemia (CML). To understand the mechanisms underlying the synergistic/additive action of these agents, we applied cDNA microarrays, component plane presentation integrated self-organizing map (CPP-SOM), and methods of protein biochemistry to study cell apoptosis induced by imatinib mesylate, ATO, and the combination of the 2 agents in the CML cell line K562. Numerous features with temporospatial relationships were revealed, indicating the coordinated regulation of molecular networks from various aspects of proapoptotic and apoptotic activities in CML. Imatinib mesylate appears to induce mainly the intrinsic pathway of cell apoptosis, whereas ATO induces the endoplasmic reticulum (ER) stress-mediated pathway of cell apoptosis, and the combination of the 2 agents seems to more effectively induce the intrinsic, extrinsic, and ER stress-mediated pathways of cell apoptosis, which results in a more effective and efficient induction of programmed cell death in K562 cells. This finding appears to be supported also by data derived from bone marrow cells of 2 patients with CML, one in chronic phase and the other in blast-crisis phase of the disease.

[1]  G. Evan,et al.  Caspase‐8 in Apoptosis: The Beginning of “The End”? , 2000, IUBMB life.

[2]  Charles Auffray,et al.  Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  K. Bhalla,et al.  Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). , 2000, Blood.

[4]  M. Peter,et al.  The TNF Receptor 1 A Split Personality Complex , 2003, Cell.

[5]  D. Bredesen,et al.  Coupling endoplasmic reticulum stress to the cell death program , 2004, Cell Death and Differentiation.

[6]  E. Arranz,et al.  Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. , 2003, Haematologica.

[7]  B. Druker.  Imatinib alone and in combination for chronic myeloid leukemia. , 2003, Seminars in hematology.

[8]  K. Antman,et al.  Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.

[9]  R. Hoffman,et al.  Regulation of megakaryocytopoiesis. , 1989, Blood.

[10]  J. Melo,et al.  In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. , 2004, Blood.

[11]  Jie Wu,et al.  Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. , 2003, Cancer research.

[12]  J. Goldman,et al.  Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs , 2002, Leukemia.

[13]  Ji Zhang,et al.  Component plane presentation integrated self‐organizing map for microarray data analysis , 2003, FEBS letters.

[14]  T. Papayannopoulou,et al.  HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. , 1982, Science.

[15]  W. Ansorge,et al.  Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27 , 1999, The EMBO journal.

[16]  Ian R Radford.  Imatinib. Novartis. , 2002, Current opinion in investigational drugs.

[17]  G. Cooper,et al.  Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. , 1995, Science.

[18]  M. Deininger.  Cytogenetic studies in patients on imatinib. , 2003, Seminars in hematology.

[19]  T. Tsuruo,et al.  Modulation of Akt kinase activity by binding to Hsp90. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Mazzarella,et al.  ERp72, an abundant luminal endoplasmic reticulum protein, contains three copies of the active site sequences of protein disulfide isomerase. , 1990, The Journal of biological chemistry.

[21]  R. Glockshuber,et al.  ERp57 Is a Multifunctional Thiol-Disulfide Oxidoreductase* , 2004, Journal of Biological Chemistry.

[22]  B. Brinkman,et al.  Splice variants as cancer biomarkers. , 2004, Clinical biochemistry.

[23]  B. Druker,et al.  Roots of Clinical Resistance to STI-571 Cancer Therapy , 2001, Science.

[24]  M. Eilers,et al.  Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. , 2001, Genes & development.

[25]  Sherry,et al.  ERp 72 , an Abundant Luminal Endoplasmic Reticulum Protein , Contains Three Copies of the Active Site Sequences of Protein Disulfide Isomerase * , 2001 .

[26]  S. Yang,et al.  Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase. , 2002, Journal of biochemistry and molecular biology.

[27]  J. Goldman,et al.  Chronic myeloid leukemia-still a few questions. , 2004, Experimental hematology.

[28]  H. Söling,et al.  The protein disulphide-isomerase family: unravelling a string of folds. , 1999, The Biochemical journal.

[29]  B. Druker,et al.  STI571: targeting BCR-ABL as therapy for CML. , 2001, The oncologist.

[30]  O. Ottmann,et al.  BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. , 2000, Cancer research.

[31]  M. Scheid,et al.  Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopoietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signalling between interleukin-3 and granulocyte-macrophage colony stimulating factor. , 1995, The Biochemical journal.

[32]  J. Eriksson,et al.  Erythroid Differentiation Sensitizes K562 Leukemia Cells to TRAIL-Induced Apoptosis by Downregulation of c-FLIP , 2003, Molecular and Cellular Biology.

[33]  J. Blenis,et al.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression , 2004, Oncogene.

[34]  W. Plunkett,et al.  Inhibition of Mitochondrial Respiration , 2003, Journal of Biological Chemistry.

[35]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[36]  Guoqiang Chen,et al.  Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. , 2004, Blood.

[37]  F. E. Bertrand,et al.  JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.

[38]  G. Jia,et al.  Protective role of metallothionein (I/II) against pathological damage and apoptosis induced by dimethylarsinic acid. , 2004, World journal of gastroenterology.

[39]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[40]  C. Barthe,et al.  Roots of clinical resistance to STI-571 cancer therapy. , 2001, Science.

[41]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[42]  J. Melo,et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.

[43]  K. Bhalla,et al.  Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells , 2001, Leukemia.